| Description | Creative Biolabs offers a range of recombinant cell lines for Immunotherapy discovery and development. | Bifidobacterium are Gram-positive, heterofermentative, anaerobic bacteria with a distinctive bifid; i.e. Y shape after which they are named. They wre originally isolated from the faeces of breast-fed infants, members of the genus Bifidobacterium are commonly found in the GI tract of mammals. In Bifidobacterium are Gram-positive, heterofermentative, anaerobic bacteria with a distinctive bifid; i.e. Y shape after which they are named. They wre originally isolated from the faeces of breast-fed infants, members of the genus Bifidobacterium are commonly found in the GI tract of mammals. In humans, Bifidobacterium resides within the GI tract, from birth to old age. Disturbances in the microbiota are linked to an ever-growing number of immune-linked disease states including IBD, atopic allergy, arthritis, and obesity. Therefore, there is a significant interest in treating these diseases through microbial or "probiotic" supplementation of patients, including Bifidobacterium. Data from mouse models and clinical trials indicate that Bifidobacterium may have beneficial effects for treating and preventing immune-linked diseases, including gut-associated and systemic conditions. Bifidobacterium have been commercially exploited as probiotic agents due to their associated health benefits and GRAS.... Read More | Creative Biolabs offers a range of recombinant cell lines for Immunotherapy discovery and development. | Recombinant Norovirus GI.1 Virus-like Particles (NoV GI.1 VLPs) are produced in Baculovirus/Insect cell expression system, assembled with VP1 structure protein. VLP is mimicking the native 3D structure of viruses which can elicit strong immune responses. However, VLPs lack viral genomic material Recombinant Norovirus GI.1 Virus-like Particles (NoV GI.1 VLPs) are produced in Baculovirus/Insect cell expression system, assembled with VP1 structure protein. VLP is mimicking the native 3D structure of viruses which can elicit strong immune responses. However, VLPs lack viral genomic material which makes them non-infectious, unable to replicate and enhance the safety during manufacture and administration. NoV GI.1 VLPs can be used in the development of NoV GI.1 diagnostics and in vaccine development and R&D (including use as an immunogen).... Read More | The product SIRGT47166WQ-2F is a type of small interfering RNA (siRNA) that targets LIN28A gene and regulates the expression of gene. The siRNA interferes with the expression of LIN28A gene with complementary nucleotide sequences by degrading mRNA after transcription, preventing translation. The The product SIRGT47166WQ-2F is a type of small interfering RNA (siRNA) that targets LIN28A gene and regulates the expression of gene. The siRNA interferes with the expression of LIN28A gene with complementary nucleotide sequences by degrading mRNA after transcription, preventing translation. The siRNA is designed with 2_-deoxy-2_-fluoro (2'-F) modification to provide increased stability, increased specificity and reduced immunogenicity. It has potential applications in RNA interference (RNAi) and gene therapy development.... Read More |